Stocks to Watch – APOL, WU, SVU, DAL
NEW YORK, JANUARY 10, 2013 — (Net PR News) – Smack Sportswear (OTC:SMAK) stock traded with volume of 1.66 million shares, while the average trading volume remained 271,639 shares. SMAK showed a downward trend of -31.62% on January 9, 2013 and closed the trading session at $0.133.
Tracking the one month performance of SNPK, it showed a bearish movement of -73.4% and it plunged -16.87% in its prior 5 days performance.
How Should Investors Trade SMAK Now? Don’t Trade SMAK Until You Read This TREND ANALYSIS REPORT
Generex Biotechnology Corporation (OTC:GNBT) started the trading session at $0.04 and, at the end of the trading day, closed at $0.0342 by scoring -16.59%.
GNBT traded with volume of 5.41 million shares, which was larger as compared to average trading volume of 2.40 million shares. The market capitalization of GNBT was $12.72 million on January 9, 2013.
A look on past trends of GNBT: The stock was a percentage loser, when we take a look at its prior 1 month performance, as it plunged -18.38%. However, the stock was a gainer, when we consider its previous 5 days performance, as it showed bullish movement of +41.32%.
How Should Investors React To GNBT Now? Find Out In This TREND ANALYSIS REPORT
Cellceutix Corp (OTC:CTIX) traded 506,538 shares, compared to average trading volume of 719,362 shares.
CTIX started the trading session at $2.15, hit the superior price edge of $2.16, and closed the session at $1.89, by showing a negative move of -12.09%.
A view on previous Trends: the 5 days graph showed the upbeat performance of +9.25%. The 3 months and 6 month performances showed it as a gainer of +92.27% and +175.91%, respectively.
CTIX provided information regarding the company’s planned European clinical trials for Kevetrin™, Cellceutix’s flagship anti-cancer compound.
Get A Free Report And Detailed Analysis On CTIX CLICK HERE To Read
The sponsors of the upcoming clinical trials are The University of Bologna in Italy, along with The Italian Cooperative Study Group on Chronic Myeloid Leukemia (ICSG on CML), plus Acute Leukemia (GIMEMA Group).
REVOLUTIONARY CONCEPTS IN (PINK:REVO) trading volume was 53.36 million shares and its average volume remained 24.34 million shares. The stock plunged -25.96% and closed the session at $0.0077.
The stock was a big gainer in its one month as well as three month’s performances and advanced +220.83% and +381.25%, respectively. REVO advanced +285% in the prior five day’s period.
Is REVO A Solid Investment At These Levels? Find Out Exactly Where REVO Is Headed With This TREND ANALYSIS REPORT
REVO and its subsidiary, Greenwood Finance Group, LLC, made an announcement regarding the launch of their latest marketing and funding strategies for the year 2013. The plans are set to include an enhanced business model with a focus on development of their client base along with diversification in funding programs.
About Fast Moving Stocks
FastMovingStock.com is engaged in providing valuable ideas and news information on U.S. stocks on a regular basis. FastMovingStock.com provides detailed research guides on small cap and large cap stocks, helping investors in making wise stock market investment decisions through its free e-newsletter to subscribers.
The assembled information disseminated by fastmovingstock.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Fast moving stock.com does not expect that investors will buy and sell securities based on information assembled and presented in fastmovingstock.com. PLEASE always do your own due diligence, and consult your financial advisor.